A blood marker cardiologists have used for years to predict heart failure outcomes turns out to be doing something far more dangerous than anyone realized: it may be actively destroying heart muscle cells from the inside.
A new study in the European Heart Journal found that soluble ST2, a protein long treated as a passive warning sign of cardiac stress, drives the progression of fulminant myocarditis by sabotaging mitochondria inside heart muscle cells. The finding reframes a biomarker doctors have measured for over a decade as something closer to a weapon.
A heart condition that can kill in 48 hours
Myocarditis is inflammation of the heart muscle, usually triggered by a viral infection. Most cases resolve with rest and go unnoticed.
Fulminant myocarditis is the rare, violent version. The heart can go from functioning normally to catastrophic failure within 48 to 72 hours, often in people who were previously healthy and physically active.
It is also one of the leading causes of sudden cardiac death in young athletes, which is why cardiologists have spent years trying to figure out which mild cases will stay mild and which will spiral.
The protein that was supposed to be just a messenger
Soluble ST2 (sST2) is already a familiar name in cardiology. It circulates as a decoy receptor that mops up a signaling molecule called IL-33, and elevated levels have long been used to flag patients at higher risk of heart failure and death.
Until now, it was treated the way most biomarkers are treated: as a readout of damage already happening elsewhere, not a cause of it. A high sST2 level told a doctor the heart was under stress, not why the stress was getting worse.
The new research challenges that assumption directly. According to the study, sST2 does not just rise in response to myocarditis, it accelerates it.
Inside the IGF2R-YY1 mitochondrial axis
The mechanism the researchers describe centers on two molecules most readers have never heard of: IGF2R and YY1.
IGF2R is a receptor that normally helps shuttle enzymes and growth factors around a cell. YY1 is a transcription factor, a protein that switches other genes on or off.
In heart muscle cells under attack from fulminant myocarditis, the study found that soluble ST2 hijacks this IGF2R-YY1 pathway and redirects it toward the mitochondria, the structures inside every cell that generate energy. Mitochondria in heart muscle are especially demanding; cardiac tissue burns through more energy per gram than almost any other tissue in the body, and a steady energy supply is what keeps the heart beating in rhythm.
Disrupting that supply through this pathway appears to push heart muscle cells toward dysfunction and death faster than the viral infection alone would. In effect, the body’s own stress-response protein turns into an accelerant once levels climb high enough, converting a recoverable inflammation into a cascading mitochondrial failure.
Why this matters beyond the hospital
Myocarditis has become a familiar word well outside cardiology wards over the past several years, largely because of its connection to viral illness and, in rarer cases, to vaccination and to pushing through a cold or flu during training.
The standard advice for anyone with a suspected viral infection and new chest pain, unusual fatigue, or palpitations has always been to stop exercising and get evaluated, precisely because exertion on an already-inflamed heart can make things worse. What this study adds is a biological reason that trajectory can turn so quickly in a small subset of cases: a molecular switch that is not visible on a stethoscope exam.
It also helps explain something clinicians have struggled with for years, which is why two patients with seemingly similar, mild-looking myocarditis can have wildly different outcomes. If sST2 is not just marking severity but manufacturing it, measuring it earlier, and potentially blocking its downstream effects, could change how high-risk cases are triaged before they become emergencies.
What the finding does not yet mean
This is a mechanistic study, identifying a biological pathway, not a clinical trial of a new drug. There is no approved therapy yet that targets the IGF2R-YY1 axis in human patients, and soluble ST2 blood tests remain a risk marker, not a diagnostic tool used to predict who will develop the fulminant form.
What the research does is open a specific, druggable target in a disease that has had very few of them. Current treatment for fulminant myocarditis still relies heavily on supportive care, mechanical circulatory support, and immunosuppression, blunt tools for a condition now shown to have a precise molecular driver.
The takeaway
For most people, a bout of viral illness and a few days of fatigue will never involve the heart at all. But the small number of cases that do turn dangerous no longer look like a mystery of bad luck.
They look, increasingly, like the result of a single overactive protein pathway, one that researchers can now see clearly enough to try to stop.
